A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer targetZachary T. Freeman, Charles G. Drake, John Engelhardt et al.|Journal of Clinical Investigation|2020Cited by 133
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trialAaron S. Mansfield, Keith T. Flaherty, Zihan Wei et al.|npj Precision Oncology|2022Cited by 42